JBT-101 in Systemic Lupus Erythematosus (SLE)

ClinicalTrials.gov ID: NCT03093402

Public ClinicalTrials.gov record NCT03093402. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 6, 2026, 6:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus

Study identification

NCT ID: NCT03093402
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Enrollment: 109 participants

Conditions and interventions

Conditions

Interventions

JBT-101 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 20, 2017
Primary completion: Jul 27, 2021
Completion: Jul 27, 2021
Last update posted: May 5, 2026

2017 – 2021

United States locations

U.S. sites: 16
U.S. states: 8
U.S. cities: 14

Facility	City	State	ZIP	Site status
University of California San Diego School of Medicine: Division of Rheumatology, Allergy and Immunology	La Jolla	California	92093	—
UCLA Medical Center: Division of Rheumatology	Los Angeles	California	90095	—
University of California San Francisco School of Medicine: Lupus Clinic and Rheumatology Clinical Research Center	San Francisco	California	94143	—
Yale University	New Haven	Connecticut	06520	—
Emory University: Division of Rheumatology	Atlanta	Georgia	30322	—
Feinstein Institute for Medical Research: Center for Autoimmune and Musculoskeletal Diseases	Manhasset	New York	11030	—
New York University Langone Medical Center: Department of Medicine, Division of Rheumatology	New York	New York	10016	—
Columbia University Medical Center: Department of Medicine, Division of Rheumatology	New York	New York	10032	—
Bronx-Lebanon Hospital Center: Division of Rheumatology	The Bronx	New York	10457	—
Duke University	Durham	North Carolina	27710	—
MetroHealth Medical Center	Cleveland	Ohio	44109	—
Penn State MS Hershey Medical Center	Hershey	Pennsylvania	17033	—
University of Pennsylvania	Philadelphia	Pennsylvania	19104	—
Temple University	Philadelphia	Pennsylvania	19140	—
University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology	Pittsburgh	Pennsylvania	15217	—
Medical University of South Carolina	Charleston	South Carolina	29425	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03093402, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 5, 2026 · Synced May 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03093402 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →